However, due to the often complex and non-linear type 2 kinetics displayed by FVIII inhibitors in AHA, the Bethesda assay may not be an ideal estimation of autoantibody’s inhibitory potential [72]. The gene discussed is F8; the disease is autoimmune hemolytic anemia.